Perioperative ischemic evaluation study (POISE study)

ISRCTN ISRCTN17233551
DOI https://doi.org/10.1186/ISRCTN17233551
ClinicalTrials.gov number NCT00182039
Secondary identifying numbers MCT-50851, ACTRN012605000308695
Submission date
19/08/2005
Registration date
19/08/2005
Last edited
25/02/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr Philip Devereaux
Scientific

Clinical Epidemiology & Biostatistics
McMaster University Health Sciences Centre
Room 2C8, 1200 Main Street West
Hamilton, Ontario
L8N 3Z5
Canada

Phone +1 905 525 9140 ext. 22063
Email philipj@mcmaster.ca

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typePrevention
Scientific title
Study acronymPOISE
Study objectivesPerioperative metoprolol will reduce the 30 day risk of major cardiovascular events in patients undergoing noncardiac surgery.
Ethics approval(s)McMaster University Research Ethics Board approved on 25th April 2002
Health condition(s) or problem(s) studiedCardiovascular
InterventionPatients will be randomly assigned to either the experimental intervention of oral metoprolol or the control intervention, a placebo. Patients will receive their first dose of metoprolol CR or placebo two to four hours pre-operatively at a strength of 100 mg (1/2 of a 200 mg tablet). Patients will then receive their second dose of their assigned intervention during the first 6 hours or at 6 hours post surgery. Twelve hours after the second post-op dose, patients will start taking a daily dose of 200 mg of either metoprolol CR or placebo for a duration of 30 days post surgery.

For further information, please contact Dr Devereaux at the address listed below or Dr Homer Yang at Ottawa Hospital (hyang@ottawahospital.on.ca).
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Metoprolol
Primary outcome measureCardiac death at 30 days, nonfatal myocardial infarction (MI), and nonfatal cardiac arrest
Secondary outcome measures1. Length of hospital stay
2. Length of stay in an ICU/CCU
3. Revascularisation procedures (i.e. coronary artery bypass surgery and percutaneous transluminal coronary angioplasty)
4. Pulmonary oedema
5. Clinically significant atrial fibrillation
6. Stroke
7. Total mortality
8. Rehospitalisation for cardiac reasons
9. Myocardial infarction
10. Nonfatal cardiac arrest
11. Cardiovascular mortality
12. Clinically significant hypotension
13. Clinically significant bradycardia
Overall study start date01/09/2002
Completion date01/04/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants10,000
Key inclusion criteria1. Greater than or equal to 45 years of age, either sex
2. Have an expected length of stay greater than or equal to 24 hours
3. Fulfill any one of the following six criteria:
3.1. Coronary artery disease
3.2. Peripheral vascular disease
3.3. History of stroke due to atherothrombotic disease
3.4. Hospitalisation for congestive heart failure within 3 years of randomisation
3.5. Undergoing major vascular surgery
3.6. Any three of the following seven criteria: scheduled for high risk surgery (i.e. intraperitoneal or intrathoracic), emergency/urgent surgery, any history of congestive heart failure, history of a transient ischaemic attack (TIA), diabetes and currently on an oral hypoglycaemic agent or insulin therapy, preoperative serum creatinine greater than 175 µmol/l (greater than 2.0 mg/dl), or age greater than 70 years
4. Are able to give written consent
Key exclusion criteria1. Contradiction to metoprolol including any of the following: significant bradycardia (heart rate less than 50 beats per minute); second or third degree heart block without a pacemaker, asthma that has been active within the last decade, and history of chronic obstructive pulmonary disease (COPD) with bronchospasm on pulmonary function tests
2. Clinical plan to use a beta-blocker preoperatively or during the first 30 postoperative days
prior adverse reaction to a beta-blocker
3. Coronary artery bypass graft (CABG) surgery with complete revascularisation in the preceding 5 years and no evidence of cardiac ischaemia since the CABG surgery
4. Patients undergoing low risk surgical procedures (potential examples include transurethral procedures [transurethral prostatectomies {TURPs}, stone baskets etc.], ophthalmologic procedures under topical or regional anaesthesia [cornea transplants, cataract surgery etc.], and surgeries with limited physiological stresses [digital re-implantation, nerve repairs etc.])
5. Concurrent use of verapamil
6. Prior enrolment in this trial
Date of first enrolment01/09/2002
Date of final enrolment01/04/2007

Locations

Countries of recruitment

  • Australia
  • Canada

Study participating centre

Clinical Epidemiology & Biostatistics
Hamilton, Ontario
L8N 3Z5
Canada

Sponsor information

McMaster University (Canada)
University/education

1200 Main Street West
Hamilton, Ontario
L8N3Z5
Canada

Phone +1 905 521 2100 ext 22465
Email townsend@mcmaster.ca
Website http://www.mcmaster.ca/
ROR logo "ROR" https://ror.org/02fa3aq29

Funders

Funder type

Research organisation

Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-50851)

No information available

National Health and Medical Research Council (NHMRC) (Australia)
Government organisation / National government
Alternative name(s)
NHMRC
Location
Australia
Australia Clinical Trials Grant (Australia)

No information available

British Heart Foundation (UK)
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
the_bhf, The British Heart Foundation, BHF
Location
United Kingdom
Astra Zeneca (International)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 31/05/2008 Yes No